Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GBA Variants and Parkinson Disease: Mechanisms and Treatments.

Cells - 8 Apr 2022

Smith Laura, Schapira Anthony H V

Abstract excerpt

The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which maintains glycosphingolipid homeostasis. Approximately 5-15% of PD patients have mutations in the GBA gene, making it numerically the most important genetic risk factor for Parkinson disease (PD). Clinically, GBA-associated PD is identical to sporadic PD, aside from the earlier age at onset (AAO), more frequent cognitive impairment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Cellular transport and secretion
Share to Endoplasmic Reticulum

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glucosylceramidase

Share to Lysosomal Storage Disorders Research

Share to Lysosomes

Share to Mutation

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 35455941
DOI: 10.3390/cells11081261
PMCID: PMC9029385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GBA Variants and Parkinson Disease: Mechanisms and Treatments.PMID 35455941Read ↗

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Semantic proximity Read ↗

The role of glucocerebrosidase in Parkinson disease pathogenesis.Semantic proximity Read ↗

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.Semantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic ImplicationsSemantic proximity Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.Semantic proximity Read ↗

GBA1-associated parkinsonism: new insights and therapeutic opportunitiesSemantic proximity Read ↗

[GBA mutations and Parkinson's disease].Semantic proximity Read ↗

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted TherapySemantic proximity Read ↗

Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.Semantic proximity Read ↗

Glucocerebrosidase mutations and Parkinson disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.